Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16494337 | 0.89 | FAAH (0.60) | ACHE | |
| SCHEMBL16494086 | 0.88 | ACHE (0.68) | ACHEALOX5EPHX2 | |
| SCHEMBL16494219 | 0.88 | ACHE (0.62) | ACHEALOX5EPHX2 | |
| SCHEMBL16494639 | 0.88 | ACHE (0.62) | ACHEMAPTSMN1; SMN2GAAALOX5 | |
| SCHEMBL16494973 | 0.86 | ACHE (0.63) | ACHEALOX5EPHX2 | |
| SCHEMBL16494625 | 0.86 | ACHE (0.63) | ACHEALOX5EPHX2 | |
| SCHEMBL16495125 | 0.86 | ACHE (0.66) | ACHEMAPTALOX5EPHX2 | |
| SCHEMBL16494110 | 0.86 | ACHE (0.60) | ACHEMAPTALOX5EPHX2 | |
| SCHEMBL16495181 | 0.85 | TNF (0.60) | ACHEMAPTALOX5EPHX2 | |
| SCHEMBL16494341 | 0.85 | ACHE (0.62) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2394990-A1 | INDOLINE DERIVATIVES | Kyoto University (JP) | 2011-12-14 | — | — | EP | disclosed |
| US-20110294850-A1 | INDOLINE DERIVATIVES | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294850-A1 | INDOLINE DERIVATIVES | BCHE, ACHE, INMT | ACHE 2/4885TP53 4595/4885MAPT 2067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.